Release Date: August 6, 2007

Valid Through: August 5, 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following:

Updates in the Management of Gastrointestinal Cancers: A Report from the 2007 WCGIC 
J. Randolph Hecht, MD, Director Gastrointestinal Oncology Program, Clinical Professor of Medicine, Jonsson Comprehensive Cancer Center, UCLA

A graduate of the University of Eastern Virginia Medical School 1984, Dr. Hecht completed his medical internship and fellowship at Northwestern University and University of Chicago.  Dr. Hecht completed his fellowship in medical hematology-oncology at UCLA in 1997, and since then, has been the Director of the Gastrointestinal Oncology program at the UCLA School of Medicine.

 Dr. Hecht's research and clinical interests concern malignancies of the gastrointestinal tract. He participates in a range of activities and is particularly interested in translating laboratory findings into improved patient care. Hecht's current research includes preclinical models of therapy with biological agents, novel imaging techniques, Phase I studies with gene therapy vectors and tyrosine kinase inhibitors, as well as leading large clinical trials evaluating inhibitors of angiogenesis and the epidermal growth factor receptor.
 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Explain results of the addition of cisplatin to gemcitabine in the treatment of locally advanced pancreatic cancer.
• Discuss the results of the use of pegfilgrastim among patients with metastatic colorectal cancer who are receiving treatment with every other week regimens.
• Understand results associated with the use of FOLFOX versus standard fluorouracil plus cisplatin in the treatment of locally advanced or inoperable esophageal cancer.
• Understand the use of markers to help predict outcomes from specific treatments in gastrointestinal cancers.
• Discuss the safety and efficacy results of the Panitumumab Advanced Colorectal Cancer Evaluation (PAACE) trial.

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an educational donation provided by Amgen.